JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoshiki Sawa
Norihide Fukushima
Goro Matsumiya
Hikaru Matsuda
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kondoh, H.
Right arrow Articles by Matsuda, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kondoh, H.
Right arrow Articles by Matsuda, H.
Related Collections
Right arrow Congestive Heart Failure

J Thorac Cardiovasc Surg 2005;130:295-302
© 2005 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy

Haruhiko Kondoh, MD a , Yoshiki Sawa, MD a , Norihide Fukushima, MD a , Goro Matsumiya, MD a , Shigeru Miyagawa, MD a , Satoru Kitagawa-Sakakida, MD b , Imran A. Memon, MD a , Naomasa Kawaguchi, MD c , Nariaki Matsuura, MD c , Hikaru Matsuda, MD a , *

a Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
b Department of Molecular Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan
c Department of Pathology, School of Allied Health Science, Faculty of Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

Received for publication July 5, 2004; revisions received October 31, 2004; accepted for publication November 2, 2004.

* Address for reprints: Hikaru Matsuda, MD, Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan (Email: matsuda{at}surg1.med.osaka-u.ac.jp).

OBJECTIVE: It has been postulated recently that changes in cytoskeletal and sarcolemmal proteins initiate a final common pathway for contractile dysfunction in dilated cardiomyopathy. In ischemic cardiomyopathy, hepatocyte growth factor plays an important role in reorganizing the impaired cytoskeletal proteins in several cell types. We have tested the hypothesis that hepatocyte growth factor might improve life expectancy through modification of the molecular process that contributes to impairment in dilated cardiomyopathy.

METHODS: Adult male 27-week-old BIO TO-2 hamsters, which show moderate cardiac remodeling, were divided into treatment groups that received (1) hemagglutinating virus of Japan liposomes containing human hepatocyte growth factor cDNA (H group), (2) culture medium (C group), or (3) sham operation (S group).

RESULTS: After the operation, echocardiography demonstrated that the enlarged left ventricular end-systolic dimension and decreased fractional shortening were significantly attenuated in the H group compared with the C group. There was significantly less myocardial fibrosis in the H group compared with the C group. Immunohistochemical analysis showed alpha-dystroglycan and alpha- and beta-sarcoglycan expression in the basement membrane beneath the cardiomyocytes in the H group, whereas no expression of these proteins was seen in the C group. The 40-week survival was significantly better in the H group than in the C and S groups.

CONCLUSION: An improved survival associated with transient reorganization of the cytoskeletal proteins and reduction in myocardial fibrosis was achieved by hepatocyte growth factor treatment in an adult hamster model of dilated cardiomyopathy. The results suggest a therapeutic potential of hepatocyte growth factor in the treatment of dilated cardiomyopathy.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, Y. Imanishi, N. Kawaguchi, N. Matsuura, and H. Matsuda
Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters
Ann. Thorac. Surg., July 1, 2007; 84(1): 134 - 141.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. Kondoh, Y. Sawa, S. Miyagawa, S. Sakakida-Kitagawa, I. A. Memon, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, and H. Matsuda
Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters
Cardiovasc Res, February 1, 2006; 69(2): 466 - 475.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.